上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02607 上海医药

未开盘 06-23 16:08:18

11.840

+0.000

0.00%

最高12.020	最低11.750	成交量273.49万
今开11.900	昨收11.840	日振幅2.28%
总市值439.03亿	流通市值108.82亿	总股本37.08亿
成交额3,249万	换手率0.30%	流通股本9.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.84,"timestamp":1782202098006,"preClose":11.84,"halted":0,"volume":2734900,"delay":0,"changeRate":0,"floatShares":919072704,"shares":3708000000,"eps":1.7770575358372207,"marketStatus":"未开盘","change":0,"latestTime":"06-23 16:08:18","open":11.9,"high":12.02,"low":11.75,"amount":32485667,"amplitude":0.022804,"askPrice":11.85,"askSize":4400,"bidPrice":11.84,"bidSize":6700,"shortable":3,"etf":0,"ttmEps":1.803366081985337,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782264600000},"marketStatusCode":0,"adr":0,"listingDate":1305820800000,"exchange":"SEHK","adjPreClose":11.84,"dividendRate":0.03788,"openAndCloseTimeList":[[1782178200000,1782187200000],[1782190800000,1782201600000]],"volumeRatio":0.7511487090591386,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.14,"timestamp":1782198000000,"preClose":15.96,"halted":0,"volume":14426000,"delay":0,"premium":"-36.43"}},"requestUrl":"/m/hq/s/02607","defaultTab":"news","newsList":[{"id":"2645224880","title":"上海医药（601607）新增【养老】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2645224880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645224880?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:30","pubTimestamp":1782131421,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，6月22日上海医药新增概念。上海医药主营业务：化学原料药、化学药制剂、抗生素、生化药品、生物制品中成药、医疗器械、制药设备、化学危险物品等的生产、销售及进出口业务。上海医药2026年一季报显示，一季度公司主营收入752.62亿元，同比上升6.36%；归母净利润14.18亿元，同比上升6.35%；扣非净利润12.38亿元，同比下降2.02%；负债率61.14%，投资收益-1411.53万元，财务费用3.57亿元，毛利率10.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200035589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","02607","BK1197","BK0184","BK0175","BK0188","BK0183","BK0209","BK0196","BK0097","601607","BK0187","BK0028","BK0012","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644724594","title":"股市必读：上海医药（601607）6月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644724594","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644724594?lang=zh_cn&edition=full","pubTime":"2026-06-18 04:55","pubTimestamp":1781729710,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，上海医药报收于16.11元，下跌0.25%，换手率0.26%，成交量7.34万手，成交额1.18亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800004043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0020","BK0188","02607","BK0012","BK0099","BK0209","BK0184","BK0187","BK0028","BK1197","BK0097","BK0196","BK0175","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644712397","title":"上海医药：控股股东已发布增持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2644712397","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644712397?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:18","pubTimestamp":1781687887,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药06月17日在投资者关系平台上答复投资者关心的问题。公司始终将市值管理作为长期战略的重要组成部分，多措并举加强市场沟通，注重股东回报。后续公司将结合实际经营状况以及现金需求来确定未来的分红比例。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700029552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","BK0188","BK0209","BK0099","BK0012","BK0184","BK0196","BK0175","BK0028","BK0187","BK1197","BK0183","BK0097","601607","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644871101","title":"上海医药(02607)：赵勇获选举为第九届董事会职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2644871101","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644871101?lang=zh_cn&edition=full","pubTime":"2026-06-17 16:42","pubTimestamp":1781685772,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，赵勇先生(赵先生)获选举为本公司第九届董事会职工代表董事。赵先生的获选无须经本公司股东于股东会上批准。赵先生将与经本公司股东会选举产生的董事共同组成本公司第九届董事会，其任期将与第九届董事会任期一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0209","BK0175","601607","02607","BK0020","BK0183","BK1197","BK0188","BK0099","BK0184","BK0196","BK0187","BK0028","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643243081","title":"上海医药获控股股东增持3860万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643243081","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643243081?lang=zh_cn&edition=full","pubTime":"2026-06-14 12:37","pubTimestamp":1781411820,"startTime":"0","endTime":"0","summary":"　　上海医药公布，2026 年 6 月 10 日，公司收到控股股东上海实业（集团）有限公司出具的告知函：2026 年 5 月 6 日至 2026 年 6 月 10 日期间，上海实业（集团）有限公司通过全资子公司上实国际累计增持公司3860万股H股。　　本次权益变动后，上海上实（集团）有限公司持有公司股票 1，484，975，837 股，占公司总股本 3，708，361，809 股的 40.04%。权益变动方式为二级市场集中竞价交易方式，增持股份的资金来源为自有资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-06-14/doc-iniciymx9108513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0020","601607","BK0188","BK0028","BK0187","BK0097","BK0012","BK1197","BK0209","BK0183","BK0196","BK0184","BK0099","BK0175","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642726168","title":"上海医药(02607)获控股股东增持3860万股 H 股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642726168","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642726168?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:44","pubTimestamp":1781257456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)公布，2026 年 6 月 10 日，公司收到控股股东上海实业(集团)有限公司(以下简称“上实集团”)出具的告知函：2026 年 5 月 6 日至 2026 年 6 月 10 日期间，上海实业(集团)有限公司通过全资子公司上实国际累计增持公司3860万股 H 股。本次权益变动后，上海上实(集团)有限公司持有公司股票 1,484,975,837 股，占公司总股本 3,708,361,809 股的 40.04%。权益变动方式为二级市场集中竞价交易方式，增持股份的资金来源为自有资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0209","02607","BK0175","BK0183","BK0020","BK0028","BK0097","BK0099","BK0012","BK0184","BK0187","BK0188","BK0196","BK1197","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642269417","title":"上海医药：罗沙司他胶囊获批生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2642269417","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642269417?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:15","pubTimestamp":1781255740,"startTime":"0","endTime":"0","summary":"上海医药公告，公司下属公司上药国风的罗沙司他胶囊收到国家药监局颁发的药品注册证书，该药品获得批准生产。罗沙司他是一种新型的口服小分子低氧诱导因子脯氨酰羟化酶抑制剂，适用于慢性肾脏病（CKD）引起的贫血，包括透析及非透析患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606123770004536.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606123770004536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","601607","BK0187","BK0175","BK0188","BK0196","BK1197","02607","BK0020","BK0099","BK0097","BK0028","BK0184","BK0012","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138036998","title":"上海医药建议派发末期股息每10股3.5元，待股东大会批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1138036998","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138036998?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:22","pubTimestamp":1780478526,"startTime":"0","endTime":"0","summary":"上海医药于2026年6月4日发布更新公告，就截至2025年12月31日止年度的末期股息派发事宜，更新了股东批准日期。根据公告，公司建议派发末期普通股息，标准为每10股派发人民币3.5元。该派息方案仍需提交股东大会审议，股东批准日期定为2026年6月25日。若H股个人股东所在国与中国签订的税收协议中股息税率高于10%但低于20%，公司也将按实际税率代扣代缴。详细税项安排可参见公司此前发布的2025年度业绩公告等相关文件。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"上海医药建议派发末期股息每10股3.5元，待股东大会批准","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640165970","title":"上海医药(02607)拟派发末期股息每10股3.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640165970","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640165970?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:21","pubTimestamp":1780478463,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，该公司拟派发截至2025年12月31日止年度的末期股息每10股人民币3.5元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0020","BK0097","BK0012","BK0187","BK0099","BK0183","BK0184","BK0188","601607","VIG","BK4588","BK1197","BK0175","BK4585","BK0209","BK0028","02607","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139288356","title":"上海医药5月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1139288356","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139288356?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:45","pubTimestamp":1780307143,"startTime":"0","endTime":"0","summary":"上海医药于2026年6月1日披露截至2026年5月31日的股份变动月报表。公告显示，公司在报告期内的法定注册股本维持人民币3,708,361,809元不变，包含H股普通股919,072,704股和未在香港联交所上市的A股普通股2,789,289,105股，各类股份数量与上月保持一致。按照上述报告，上海医药的已发行股份总数未发生变化，公司确认遵守香港联交所《上市规则》及相关法律规定，月报由联席公司秘书钟涛提交。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638638206","title":"上海医药(601607.SH)子公司山东信谊成为盐酸曲唑酮片上市许可持有人","url":"https://stock-news.laohu8.com/highlight/detail?id=2638638206","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638638206?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:37","pubTimestamp":1779953868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属山东信谊制药有限公司(简称“山东信谊”)收到国家药品监督管理局颁发的《药品补充申请批准通知书》(通知书编号：2026B02904)，其同意将盐酸曲唑酮片上市许可持有人变更为山东信谊制药有限公司。盐酸曲唑酮片是河北龙海药业股份有限公司于2025年在中国批准上市的产品，适用于抑郁症的治疗，对伴有或不伴有焦虑的患者均有效。2026年5月，山东信谊就该药品上市许可持有人变更向国家药监局提出注册上市申请并获批准。截至公告日，公司针对该药品已投入约人民币520万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1197","02607","IPOS","BK0209","BK0183","BK0012","BK0097","BK0184","601607","BK0196","BK0099","BK0020","BK0175","BK0028","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638689943","title":"上海医药（601607）披露2026年中期分红安排公告，5月27日股价上涨0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638689943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638689943?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:37","pubTimestamp":1779892632,"startTime":"0","endTime":"0","summary":"截至2026年5月27日收盘，上海医药报收于16.39元，较前一交易日上涨0.31%，最新总市值为607.8亿元。该股当日开盘16.35元，最高16.42元，最低16.09元，成交额达1.84亿元，换手率为0.41%。近日，上海医药集团股份有限公司发布《关于2026年中期分红安排的公告》。该议案尚需提交公司2025年年度股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700046303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0097","BK0012","BK0187","BK0099","BK0183","BK0184","BK0188","601607","BK1197","BK0175","BK0209","BK0028","02607","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638683269","title":"上海医药：公司工业板块覆盖化学和生物药品、现代中药和保健品、医疗器械等范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2638683269","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638683269?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:33","pubTimestamp":1779885180,"startTime":"0","endTime":"0","summary":"证券日报网5月27日讯 ，上海医药在接受调研者提问时表示，公司工业板块覆盖化学和生物药品、现代中药和保健品、医疗器械等范围，聚焦免疫、精神神经、肿瘤、心血管、消化代谢及抗感染等疾病领域。公司在国内12个省市以及海外建有药品生产基地，常年生产约800个药品品规，30多种剂型。2025年公司实现工业销售过亿产品数量40个，其中过10亿产品数量4个。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677953.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["601607","BK0209","09996","BK0183","BK1583","159883","BK0099","BK0175","BK0184","BK1100","02607","BK0020","BK0097","BK0028","BK1574","BK0188","BK0012","BK0196","BK1197","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638832606","title":"上海医药：截至2026年第一季度B001项目用于治疗视神经脊髓炎（NMOSD）的III期临床试验主研究（RCP）已完成揭盲","url":"https://stock-news.laohu8.com/highlight/detail?id=2638832606","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638832606?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:32","pubTimestamp":1779885120,"startTime":"0","endTime":"0","summary":"证券日报网5月27日讯，上海医药在接受调研者提问时表示，截至2026年第一季度，B001项目用于治疗视神经脊髓炎(NMOSD)的III期临床试验主研究(RCP)已完成揭盲。研究结果显示，B001较安慰剂可显著降低AQP4-IGG阳性NMOSD的复发风险；并且B001较已获批同类药物具备更好的安全性，输液相关不良反应、感染相关不良反应、免疫球蛋白降低和血液学相关不良反应的发生率均更低。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677917.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0097","BK0188","02607","BK0175","BK0196","III","BK1197","BK0099","601607","BK0183","BK0209","BK0012","BK0020","BK0028","BK4134","BK0187","BK0184"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638268325","title":"上海医药：公司始终致力于优化业务结构，提升盈利水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2638268325","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638268325?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:32","pubTimestamp":1779885120,"startTime":"0","endTime":"0","summary":"证券日报网5月27日讯，上海医药在接受调研者提问时表示，公司始终致力于优化业务结构，提升盈利水平，确保高质量发展。一方面对于存量业务，通过进一步提质增效，优化成本结构，保持毛利水平。另一方面，通过巩固创新业务优势和开拓第二增长曲线，打造新的增长引擎。在现金流管理方面，公司始终高度重视现金流安全，坚持审慎稳健的财务管控原则，通过应收账款管理、严控资本开支、优化营运资本周转等方式筑牢资金安全底线，保障公司持续健康运营。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk9145408.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk9145408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0183","BK0097","BK1197","BK0020","601607","BK0209","BK0099","BK0012","BK0196","BK0188","BK0184","BK0187","02607","BK0028","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638503976","title":"上海医药(02607)：杨秋华、沈波、李永忠及董明获提名为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2638503976","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638503976?lang=zh_cn&edition=full","pubTime":"2026-05-27 17:06","pubTimestamp":1779872765,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，于2026年5月27日召开的董事会会议上，提名第九届董事会董事候选人名单如下：(i)杨秋华先生、沈波先生、李永忠先生及董明先生为第九届董事会的执行董事;(ii)张文学先生为第九届董事会的非执行董事;(iii)王忠先生、万钧女士、薛云奎先生及王迁先生为第九届董事会的独立非执行董事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0209","BK1197","BK0012","BK0099","BK0097","02607","BK0187","BK0028","BK0183","BK0188","601607","BK0184","BK0020","BK0196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634041495","title":"每周股票复盘：上海医药（601607）利伐沙班片获泰国注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2634041495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634041495?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:29","pubTimestamp":1778351351,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，上海医药报收于17.07元，较上周的17.09元下跌0.12%。本周，上海医药5月7日盘中最高价报17.2元。本周关注点公司公告汇总：利伐沙班片获泰国药品注册证书，具备上市销售资格。2025年5月该药品已获美国FDA批准，2025年10月获马来西亚注册证书，2026年2月获新加坡注册证书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0097","BK0184","02607","BK0099","BK0187","BK0028","BK0196","601607","BK1197","BK0188","BK0020","BK0012","BK0209","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633431583","title":"上海医药（601607）披露持股5%以上股东权益变动触及1%刻度的提示性公告，5月8日股价下跌0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633431583","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633431583?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:35","pubTimestamp":1778232954,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，上海医药报收于17.07元，较前一交易日下跌0.35%，最新总市值为633.02亿元。本次权益变动后，控股股东及其一致行动人合计持股比例由38.03%上升至39.00%，增持行为符合相关法律法规，未触发强制要约收购义务，不导致公司控制权变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800031515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0097","BK0012","BK0187","BK0099","BK0183","BK0184","BK0188","601607","BK1197","BK0175","BK0209","BK0028","02607","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633116429","title":"东南亚市场再下一城：上海医药附属公司利伐沙班片在泰国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2633116429","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633116429?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:36","pubTimestamp":1778142960,"startTime":"0","endTime":"0","summary":"5月7日，上海医药（601607/02607）发布公告，公司下属常州制药厂有限公司生产的利伐沙班片收到泰国食品药品监督管理局颁发的药品注册证书，该药品获得批准上市。利伐沙班片主要用于降低非瓣膜性房颤患者卒中和全身性栓塞的风险、治疗和预防深静脉血栓形成、用于治疗肺栓塞及预防急性病患者静脉血栓栓塞等。截至本公告日，公司针对该药品在东南亚市场上市另投入的研发费用约324.82万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605073730110589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0188","BK0209","IPOS","BK0196","BK0099","BK0020","BK0097","02607","601607","BK0028","BK0175","BK1197","BK0187","BK0184","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633974268","title":"大摩：上海医药(02607)首季业绩符预期 予上海医药(601607.SH)A股“与大市同步”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2633974268","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633974268?lang=zh_cn&edition=full","pubTime":"2026-05-06 10:14","pubTimestamp":1778033691,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，上海医药(02607)首季收入为753亿元人民币，同比增长6.4%，纯利为14.18亿元人民币，同比增长6.4%，两者均符合该行预期。大摩提到，上海医药目前正与美国及欧盟跨国的企业，就其研发管线的潜在业务发展机会进行磋商。该行予上海医药(601607.SH)A股“与大市同步”评级，目标价18.8元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","399300","159982","601607"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shaphar.com.cn","stockEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":0.0094},{"period":"3month","weight":0.0478},{"period":"6month","weight":0.0329},{"period":"1year","weight":0.074},{"period":"ytd","weight":0.0404}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0886},{"period":"3month","weight":-0.0789},{"period":"6month","weight":-0.0962},{"period":"1year","weight":-0.0149},{"period":"ytd","weight":-0.0895}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海医药集团股份有限公司是一家主要从事医药分销业务的中国公司。该公司主要经营四个业务分部。工业分部主要从事药品及保健品的研发、生产和销售。分销分部主要从事向医药制造商及配药商提供分销、仓储和其他增值医药供应链解决方案及相关服务。零售分部主要从事经营及加盟零售药店网络。其他分部主要从事其他业务。该公司主要在国内市场经营其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.005835},{"month":2,"riseRate":0.533333,"avgChangeRate":0.014987},{"month":3,"riseRate":0.533333,"avgChangeRate":0.009535},{"month":4,"riseRate":0.533333,"avgChangeRate":0.000642},{"month":5,"riseRate":0.466667,"avgChangeRate":-0.003715},{"month":6,"riseRate":0.5,"avgChangeRate":-0.007843},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.017077},{"month":8,"riseRate":0.4,"avgChangeRate":0.011563},{"month":9,"riseRate":0.333333,"avgChangeRate":0.013086},{"month":10,"riseRate":0.266667,"avgChangeRate":-0.021401},{"month":11,"riseRate":0.466667,"avgChangeRate":0.029705},{"month":12,"riseRate":0.533333,"avgChangeRate":-0.012575}],"exchange":"SEHK","name":"上海医药","nameEN":"SH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,02607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}